Sensitivity analysis: net effect of donation on survival and ESRD in 40-year-old ideal donors assuming reduced future population risks
| Donation effects | White male | White female | Black male | Black female |
| Remaining life years, non-donor | 41.100 years (41.017 to 41.298)* | 45.571 years (45.397 to 45.810) | 37.236 years (37.006 to 37.317) | 43.352 years (43.142 to 43.655) |
| Lost life years (%) postdonation | −0.572 (1.39%) (−0.489 to –0.770) | −0.462 (1.0%) (−0.162 to –0.575) | −0.799 (2.1%) (−0.699 to –1.011) | −0.824 (1.9%) (−0.614 to –1.127) |
| Remaining QALYs, non-donor | 22.431 QALYs (22.404 to 22.492) | 23.765 QALYs (23.712 to 23.834) | 20.954 QALYs (20.918 to 21.022) | 22.806 QALYs (22.743 to 22.890) |
| Lost QALYs (%) postdonation | −0.191 (0.85%) (−0.164 to –0.252) | −0.143 (0.62%) (−0.049 to –0.171) | −0.292 (1.39%) (−0.257 to –0.360) | −0.260 (1.14%) (−0.197 to –0.344) |
| Cumulative ESRD, non-donor % | 0.43% (0.185 to 0.584) | 0.29% (0.133 to 0.469) | 1.00% (0.487 to 1.374) | 0.851% (0.371 to 1.354) |
| Added cumulative ESRD % postdonation | +1.59 (1/63) (1/54 to 1/69) | +0.643% (1/155) (1/100 to 1/324) | +3.80% (1/26) (1/23 to 1/28) | +2.85% (1/35) (1/30 to 1/43) |
*Values in parentheses represent the impact of higher and lower cumulative risks of ESRD taken from the upper and lower bounds of the 95% CIs for lifetime cumulative risk of ESRD (online supplementary ref 11).
ESRD, end-stage renal disease; QALYs, quality-adjusted life years.